Considering high selective pressure and mutation rate during tumour development, and potential metabolic burden caused by PLA2R1-overexpression, it seems unreasonable to assume that PLA2R1 has a tumour-suppressive function in PC-3. The gene discussed is PLA2R1; the disease is neoplasm.